Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Merck & Co (NY: MRK ) 101.88 -0.44 (-0.43%) Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Merck & Co < Previous 1 2 3 4 5 6 7 8 9 ... 94 95 Next > 3 Magnificent Stocks Under $100 to Buy in November Today 6:41 EST The price could be right for these stocks. Via The Motley Fool 2 Dividend Stocks to Buy for a Lifetime of Passive Income November 02, 2024 These are the kinds of stocks that can allow investors to sleep easy at night. Via The Motley Fool Merck's Gardasil Shot Challenges To Continue, Analysts Optimistic For Newly Approved Sotatercept For Rare Lung Disease November 01, 2024 Merck's Q3 revenue rises, led by Keytruda's strong 17% YoY growth. Gardasil demand challenges in China impact sales, with Winrevair showing promising performance. Via Benzinga Is Merck Stock a Buy? November 01, 2024 The next few years might get bumpy for the pharmaceutical giant, but the longer term looks better. Via The Motley Fool Merck (MRK) Q3 2024 Earnings Call Transcript October 31, 2024 MRK earnings call for the period ending September 30, 2024. Via The Motley Fool Topics Earnings Exposures Financial Merck Q3 Earnings And Revenues Top Estimates October 31, 2024 Merck came out with quarterly earnings of $1.57 per share. Via Talk Markets NYSE:MRK stands out as a stock that provides good value for the fundamentals it showcases. October 30, 2024 MERCK & CO. INC. (NYSE:MRK) is an undervalued gem with solid fundamentals. Via Chartmill A Look Into Merck & Co Inc's Price Over Earnings October 29, 2024 Via Benzinga Where Will Merck Be in 5 Years? October 25, 2024 There's a lot to like here. Via The Motley Fool Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review November 01, 2024 The major indexes declined, but haven't fallen apart. Via Investor's Business Daily Merck Beats Q3 Estimates, But Lowers Annual Forecast As Gardasil Vaccine Hit By Low China Demand October 31, 2024 Merck reports Q3 sales of $16.7 billion, up 4% year-over-year, with Keytruda revenue rising 17%. EPS beats estimates; 2024 guidance updated on global demand shifts. Via Benzinga Will Merck's Guidance Cut Prove Gruesome In The Wake Of Januvia, Gardasil Misses? October 31, 2024 The company also reported light sales of HPV vaccine Gardasil and diabetes meds Januvia/Janumet. Via Investor's Business Daily (MRK) - Analyzing Merck & Co's Short Interest October 22, 2024 Via Benzinga Stocks Tumble, Nasdaq 100 Selloffs As Tech Giants Disappoint, Crypto Companies Plummet: What's Driving Markets Thursday? October 31, 2024 Risk aversion swept across markets on Thursday as investor disappointment over third-quarter tech earnings triggered the steepest drop in major U.S. indices in nearly two months. Via Benzinga 3 Dividend Stocks That Could Raise Their Payouts in November October 31, 2024 These dividend stocks can be excellent options for buy-and-hold investors. Via The Motley Fool Merck Announces Third-Quarter 2024 Financial Results October 31, 2024 From Merck & Co., Inc. Via Business Wire Why Is Moderna Stock Trading Higher On Monday? October 28, 2024 Merck and Moderna initiate Phase 3 trial of mRNA-4157 (V940) with Keytruda as adjuvant for NSCLC patients, marking progress in individualized cancer therapies. Via Benzinga Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC) October 28, 2024 From Merck & Co., Inc. Via Business Wire What Lies In Store For Healthcare ETFs In Q3 Earnings? October 27, 2024 The healthcare sector has performed well in recent months, driven by the booming weight-loss drug treatment segment. As such, various healthcare ETFs have benefited. Via Talk Markets Topics ETFs Pfizer, Live Nation Entertainment And More On CNBC's 'Final Trades' October 25, 2024 Pfizer shares fell 0.8% to close at $28.64 during Thursday's session. Live Nation Entertainment shares gained 1.5% to close at $116.45. Via Benzinga CDC And Prevention Advisory Panel Backs Expanded Use Of Pfizer And Merck's Pneumococcal Vaccines October 24, 2024 The CDC recommends expanding pneumococcal vaccine eligibility to adults aged 50 and above, impacting disease prevention with Pfizer and Merck's vaccines. Via Benzinga 3 Absurdly Cheap Stocks That Pay High Dividends October 24, 2024 These stocks are trading at less than 15 times their expected future profits. Via The Motley Fool Merck’s KEYTRUDA® (pembrolizumab) Receives 30th Approval From European Commission With Two New Indications in Gynecologic Cancers October 24, 2024 From Merck & Co., Inc. Via Business Wire CDC’S ACIP Recommends Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults 50 Years of Age and Older October 23, 2024 From Merck & Co., Inc. Via Business Wire 800% Upside For This Biotech Stock - Analyst Initiates Coverage On Bladder Cancer Focused ImmunityBio October 23, 2024 EF Hutton rates ImmunityBio (IBRX) as a Buy with a $30 target. Anktiva shows promise in cancer treatment, boosting response rates and survival outcomes. Via Benzinga Healthcare Sector Update: Choppy Days Are Here Again As Yields Rise October 22, 2024 There has been a shift in healthcare stock performance by sub-sector which should be confirmed as we move through the Q3 earnings cycle. Via Talk Markets Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks October 21, 2024 Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable success... Via Benzinga Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48 October 19, 2024 From Gilead Sciences, Inc. Via Business Wire After Failed Confirmatory Trial, Gilead Withdraws US Accelerated Approval Of Trodelvy As Bladder Cancer treatment October 18, 2024 Gilead Sciences is set to withdraw Trodelvy's accelerated approval for metastatic urothelial cancer following unsatisfactory results from the TROPiCS-04 study. However, the decision does not impact... Via Benzinga Merck Virus Treatment Shows 60.4% Effectiveness, Reduces Certain Infections In Infants October 18, 2024 Merck announces positive results from Phase 2b/3 and interim Phase 3 trials of a monoclonal antibody designed to protect infants from RSV. Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 ... 94 95 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
